Need Help?

The Precision Medicine in Liver Cancer across an Asia-pacific NETwork (PLANET) - Intratumoural immune heterogeneity

The clinical relevance of immune landscape intratumoural heterogeneity (immune-ITH) and its role in tumour evolution remain largely unexplored. Here, we uncover significant spatial and phenotypic immune–ITH from multiple tumour sectors and decipher its relationship with tumour evolution and disease progression in hepatocellular carcinomas (HCC). Immune–ITH is associated with tumour transcriptomic-ITH, mutational burden, and distinct immune microenvironments. Tumours with low immune–ITH experience higher immunoselective pressure and escape via loss of heterozygosity in human leukocyte antigens and immunoediting. Instead, the tumours with high immune-ITH evolve to a more immunosuppressive/exhausted microenvironment. This gradient of immune pressure along with immune-ITH represents a hallmark of tumour evolution, which is closely linked to the transcriptome-immune networks that contributes to disease progression and immune inactivation. Remarkably, high immune-ITH and its transcriptomic signature are predictive for worse clinical outcome in HCC patients. This in-depth investigation of ITH provides evidence on tumour-immune co-evolution along HCC progression.

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID Description Technology Samples
EGAD00001006570 HiSeq X Ten Illumina HiSeq 4000 70
EGAD00001008647 HiSeq X Ten Illumina HiSeq 4000 -
EGAD00001008648 Illumina HiSeq 4000 -
EGAD00001009041 -
EGAD00001009042 18
EGAD00001009858 HiSeq X Ten Illumina HiSeq 4000 12
EGAD00001009859 Illumina HiSeq 4000 -
Publications Citations
Intratumoural immune heterogeneity as a hallmark of tumour evolution and progression in hepatocellular carcinoma.
Nat Commun 12: 2021 227
66
Trajectory of immune evasion and cancer progression in hepatocellular carcinoma.
Nat Commun 13: 2022 1441
26
GATA4 downregulation enhances CCL20-mediated immunosuppression in hepatocellular carcinoma.
Hepatol Commun 8: 2024 e0508
0